Rx-to-OTC Switches in the EU: What the Dossier and the Procedure Must Show

Moving a medicine from prescription-only to non-prescription status is a regulatory variation with a strategic payload. The authority has to be satisfied that patients can use the product safely without a prescriber, and the dossier has to prove it.

The legal framework

Directive 2001/83/EC sets criteria for prescription status in Article 71. Medicines must be prescription-only if, for example, they may present a danger if used without medical supervision, are frequently used incorrectly, or contain substances whose activity needs further investigation. A switch must therefore show that these concerns do not apply for the proposed indication, dose and pack.

Article 74a provides that, where a classification change was based on significant pre-clinical tests or clinical trials, the authority does not refer to those results when examining another applicant’s request for a change for the same substance for one year after the first change is authorised. This can shape timing and evidence strategy.

What the dossier needs to show

  • A safety profile that supports use without supervision, including post-marketing data and the experience of misuse, overdose and interactions.
  • Self-diagnosis: patients must be able to recognise the condition and know when to seek medical advice.
  • Self-selection and dosing: label comprehension and the ability to follow the instructions, ideally supported by consumer research or actual-use studies.
  • Restricted pack size, strength, duration of use and maximum daily dose, where appropriate.

Product information and risk management

Label and leaflet need rewriting for lay users. Warnings, contraindications and a clear statement of when to stop and consult a professional are central, and readability testing becomes critical. Plan how safety will be monitored after the switch, since the patient population and exposure typically change.

Procedurally, the route depends on how the product is authorised. A change of classification may be handled nationally, or through the variation framework and the relevant procedure for products with multiple member state approvals. Classification can differ between countries, so the rationale must be robust.

Commercial dimensions

Switching alters reimbursement, advertising rules and distribution. Non-prescription medicines can be advertised to the public within national rules, while reimbursement usually falls away. Weigh these consequences before filing.

Considering the lifecycle

Think beyond approval. After a switch, pharmacovigilance expectations remain, and the marketing authorisation holder should be ready to monitor reports from a broader population. Aggregate reviews and periodic safety updates should explicitly consider the change in use pattern, and the risk management plan may need to be revised. Engage with pharmacists and patient organisations on the content of the leaflet, since their feedback often highlights points that regulators will also raise. A switch dossier that anticipates the post-switch monitoring plan is easier to approve and easier to defend later.

How PQRA helps

PQRA can assess switch feasibility against the legal criteria, design the supporting evidence package including label comprehension work, rewrite the product information for lay use and manage the classification change with the competent authority, including the EOF where Greece is involved.

Contact PQRA to discuss your dossier and procedure.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *